Nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease approved by DCGI

May 20, 2020: Drugs Controller General of India (DCGI) has approved Nintedanib by Boehringer Ingelheim (India) in treating systemic sclerosis-associated interstitial lung disease (SSc-ILD) in adults.

Earlier on 3rd March, Subject Expert Committe (CDSCO) had formulated an opnion for Nintedanib in treatment of SSc-ILD.

Systemic sclerosis (SSc) is a rare connective tissue disease that is believed to be triggered, in genetically susceptible individuals, by environmental events. It is also characterised by immune dysfunction, vasculopathy, cellular inflammation and fibrosis of the skin and multiple internal organs. When the lungs are affected, it can cause interstitial lung disease (ILD), known as SSc-ILD1. ILD is a leading cause of mortality, accounting for almost 35 per cent of SSc-related deaths.

Sharad Tyagi, MD, Boehringer Ingelheim India said that “Systemic sclerosis is a life- altering condition and Nintedanib is the first and only approved treatment for SSc-ILD, serving a high unmet need making a real positive difference. For the treatment of people living with SSc-ILD, this is a quantum leap. The DCGI approval is a milestone in Boehringer Ingelheim’s dedication towards providing the best possible treatment for people living with SSc-ILD in India.”

The approval by DCGI’s is based upon the results of the SENSCIS a Phase III trial, double-blind, placebo-controlled trial conducted to investigate the efficacy and safety of Nintedanib in patients with SSc-ILD.1 The annual rate of decline in Forced Vital Capacity (FVC) assessed over a 52-week period.

Results laid down that Nintedanib slowed the loss of pulmonary function by 44 per cent (41mL/year) relative to placebo, as measured in FVC over 52 weeks. Results have also showed that Nintedanib had a safety and tolerability profile similar to that observed in patients with idiopathic pulmonary fibrosis (IPF).

Several countries have also granted regulatory approvals for the treatment of patients living with SSc-ILD in several countries including EU, Canada, Japan and Brazil. Nintedanib is approved in over 75 countries for the treatment of IPF and it is the first approved treatment for SSc-ILD.

  • Related Posts

    • Pharma
    • March 27, 2024
    • 104 views
    Spurious drugs: Maiden Pharma blacklisted, all contracts cancelled

    Haryana has blacklisted Maiden Pharmaceuticals Ltd, based at Sonepat, for three years, thereby debarring the firm from participating in state tenders. All rate contracts issued to the firm have also…

    • Pharma
    • March 27, 2024
    • 69 views
    DCC Calls For Strict Implementation Of Revised Schedule M, State-Level Activities To Address AMR

    New Delhi: The Drugs Consultative Committee (DCC), the advisory committee formed by the Central government to advise the Central and state governments on matters that require uniform implementation of drug laws…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Spurious drugs: Maiden Pharma blacklisted, all contracts cancelled

    Spurious drugs: Maiden Pharma blacklisted, all contracts cancelled

    DCC Calls For Strict Implementation Of Revised Schedule M, State-Level Activities To Address AMR

    DCC Calls For Strict Implementation Of Revised Schedule M, State-Level Activities To Address AMR

    Sanofi, Cipla Join Hands To Expand Reach Of CNS Portfolio In India

    Sanofi, Cipla Join Hands To Expand Reach Of CNS Portfolio In India

    Cyberabad Police Seize 1 Kg Alprazolam, Arrest Three

    Cyberabad Police Seize 1 Kg Alprazolam, Arrest Three

    Lee Health develops natural capsule for effective Heart care

    Lee Health develops natural capsule for effective Heart care

    Medical Shop Run By Twenty20 In Kizhakkambalam Asked To Shut Down

    Medical Shop Run By Twenty20 In Kizhakkambalam Asked To Shut Down